Revance Therapeutics Investors Urged to Seek Legal Advice
Revance Therapeutics, Inc. is currently facing a situation that has prompted alarm among its investors. The recent legal developments have led Glancy Prongay & Murray LLP, a distinguished national shareholder rights law firm, to announce that a class action lawsuit is being pursued on behalf of investors who have purchased or acquired securities of Revance (NASDAQ: RVNC).
Understanding the Situation
Recent disclosures from Revance, dated September 23, have made waves in the investor community. Revance reported to the U.S. Securities and Exchange Commission that it received a notice addressing serious allegations of material breaches. These included exceeding buffer stock levels and shortcomings in efforts to market and sell Teoxane products as stipulated in their distribution agreement with Teoxane SA. This revelation raised eyebrows and led to significant concerns regarding the company’s operational integrity.
This news had a direct impact on the stock price of Revance, which dropped by $0.44, a staggering 7.7%, closing at $5.37 per share on the same day. The market's response illustrates the investors' anxiety about the company's future.
Further Developments Signal Trouble
The troubling news did not end there. On December 9, additional disclosures from Revance concerning an amended merger agreement with Crown Laboratories, Inc. revealed that Crown intended to pursue a tender offer to acquire all outstanding shares of Revance’s common stock at a considerably reduced price of $3.10 per share — marking a decline of more than 50% from earlier valuations.
This announcement inevitably contributed to further investor distress, with Revance's stock plummeting to $3.03 per share, experiencing a decline of $0.79 or 20.7%. Investors again faced the harsh realities of potential losses.
Legal Implications of Shareholder Claims
The lawsuit filed by Glancy Prongay & Murray LLP accuses the defendants of multiple failures, alleging that throughout the class period, they made materially false and misleading statements while not disclosing adverse facts about the company. These failures potentially exposed investors to undue risks.
Specifically, the complaint states that the management downplayed the severe breaches of the Distribution Agreement and omitted details regarding litigation risks and the potential financial repercussions for the company. This misleading information left investors in a vulnerable position, having acted on the assumption that the company was on stable ground.
Next Steps for Affected Investors
The critical takeaway for investors is the opportunity to partake in the legal actions. Those who acquired Revance securities during the class period have the chance to step forward. They may submit a request to the court to be appointed as lead plaintiff in the class action lawsuit, but the deadline for this request is approaching quickly on March 4, 2025.
Investors are encouraged to reach out if they wish to explore their options regarding participation in this class action. They can do so by getting in touch with Glancy Prongay & Murray LLP, where further information and assistance can be provided.
Contact Information for Inquiries
For any inquiries related to this class action or concerns regarding their investment in Revance Therapeutics, affected investors can contact:
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles, California 90067
Telephone: 310-201-9150,
Toll-Free: 888-773-9224
Frequently Asked Questions
What is the current situation with Revance Therapeutics?
Revance Therapeutics is facing a class action lawsuit due to allegations of securities fraud that could have significant implications for its investors.
How did Revance's stock perform recently?
The stock price has seen considerable drops following significant announcements regarding breaches in their distribution agreements and an amended merger offer.
What should investors do if they suffered losses?
Affected investors are encouraged to contact legal counsel to explore potential actions, including joining the class action lawsuit.
What is the deadline to file a claim in this lawsuit?
Investors must file a lead plaintiff motion by March 4, 2025, in order to participate in the class action.
How can I get more information about the lawsuit?
Investors can learn more by reaching out to Glancy Prongay & Murray LLP directly for details regarding their rights and options.
